Evidence map›Paper›PMID 27073096›Full record

ArticlemBio2016

Apolipoprotein L1 Variant Associated with Increased Susceptibility to Trypanosome Infection.

Bart Cuypers, Laurence Lecordier, Conor J Meehan, Frederik Van den Broeck, Hideo Imamura, Philippe Büscher, Jean-Claude Dujardin, Kris Laukens, Achim Schnaufer, Caroline Dewar and 12 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 38 citations in OpenAlex.

  1. Update on APOL1 and chronic kidney diseases in children.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  2. Article
  3. Apolipoproteins L involvement in immunity.Journal of human immunity · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Kidney medicine · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Defining Risk in APOL1-Associated Kidney Disease: The Story is Evolving!American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 4 countries.

Bart CuypersBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium Advanced Database Research and Modelling (ADReM), Department of Mathematics and Computer Science, University of Antwerp, Antwerp, Belgium.
Laurence LecordierLaboratory of Molecular Parasitology, Université Libre de Bruxelles, Gosselies, Belgium.
Conor J MeehanBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
Frederik Van den BroeckBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
Hideo ImamuraBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
Philippe BüscherBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
Jean-Claude DujardinBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
Kris LaukensAdvanced Database Research and Modelling (ADReM), Department of Mathematics and Computer Science, University of Antwerp, Antwerp, Belgium.
Achim SchnauferInstitute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdom.
Caroline DewarInstitute of Immunology and Infection Research, University of Edinburgh, Edinburgh, United Kingdom.
Michael LewisDepartment of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Oliver BalmerDepartment of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Thomas AzuragoDisease Control and Prevention Department, Ghana Health Service, Accra, Ghana.
Sardick Kyei-FariedDisease Control and Prevention Department, Ghana Health Service, Accra, Ghana.
Sally-Ann OheneWorld Health Organization Country Office in Ghana, Accra, Ghana.
Boateng DuahGhana Ports and Harbours Authority Hospital, Takoradi, Ghana.
Prince HomiahGhana Ports and Harbours Authority Hospital, Takoradi, Ghana.
Ebenezer Kofi MensahPublic Health Reference Laboratory, Takoradi, Ghana.
Francis AnleahGhana Health Service, Takoradi, Ghana.
Jose Ramon FrancoDepartment of Control of Neglected Diseases, World Health Organization, Geneva, Switzerland.
Etienne PaysLaboratory of Molecular Parasitology, Université Libre de Bruxelles, Gosselies, Belgium.
Stijn DeborggraeveBiomedical Sciences Department, Institute of Tropical Medicine Antwerp, Antwerp, Belgium sdeborggraeve@itg.be.
Instituut voor Tropische Geneeskunde · BEGhana Health Service · GHUniversité Libre de Bruxelles · BEUniversity of Edinburgh · GBSwiss Tropical and Public Health Institute · CHUniversity of Antwerp · BEUniversity of London · GBWorld Health Organization · CH

Funding

Medical Research Council MR/L019701/1World Health Organization 001
6 · The paper itself

Abstract

unlabelledAfrican trypanosomes, except Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, which cause human African trypanosomiasis, are lysed by the human serum protein apolipoprotein L1 (ApoL1). These two subspecies can resist human ApoL1 because they express the serum resistance proteins T. b. gambiense glycoprotein (TgsGP) and serum resistance-associated protein (SRA), respectively. Whereas in T. b. rhodesiense, SRA is necessary and sufficient to inhibit ApoL1, in T. b. gambiense, TgsGP cannot protect against high ApoL1 uptake, so different additional mechanisms contribute to limit this uptake. Here we report a complex interplay between trypanosomes and an ApoL1 variant, revealing important insights into innate human immunity against these parasites. Using whole-genome sequencing, we characterized an atypical T. b. gambiense infection in a patient in Ghana. We show that the infecting trypanosome has diverged from the classical T. b. gambiense strains and lacks the TgsGP defense mechanism against human serum. By sequencing the ApoL1 gene of the patient and subsequent in vitro mutagenesis experiments, we demonstrate that a homozygous missense substitution (N264K) in the membrane-addressing domain of this ApoL1 variant knocks down the trypanolytic activity, allowing the trypanosome to avoid ApoL1-mediated immunity. IMPORTANCE: Most African trypanosomes are lysed by the ApoL1 protein in human serum. Only the subspecies Trypanosoma b. gambiense and T. b. rhodesiense can resist lysis by ApoL1 because they express specific serum resistance proteins. We here report a complex interplay between trypanosomes and an ApoL1 variant characterized by a homozygous missense substitution (N264K) in the domain that we hypothesize interacts with the endolysosomal membranes of trypanosomes. The N264K substitution knocks down the lytic activity of ApoL1 against T. b. gambiense strains lacking the TgsGP defense mechanism and against T. b. rhodesiense if N264K is accompanied by additional substitutions in the SRA-interacting domain. Our data suggest that populations with high frequencies of the homozygous N264K ApoL1 variant may be at increased risk of contracting human African trypanosomiasis.

Indexed as

Disease SusceptibilityGenetic VariationApolipoprotein L1ApolipoproteinsHumansImmunity, InnateLipoproteins, HDLMutation, MissensePolymorphism, Single NucleotideProtozoan ProteinsTrypanosoma brucei gambienseTrypanosoma brucei rhodesienseTrypanosomiasis, AfricanAPOL1 protein, humanApolipoprotein L1ApolipoproteinsLipoproteins, HDLProtozoan Proteins

Identifiers

PMID27073096
PMCPMC4959518
OpenAlexW2339336535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.